• Skip to main content
  • Skip to footer
UK Plans to phase out animal testing UK Plans to phase out animal testing
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Technology
  • Products
    • PhysioMimix® Core Microphysiological System
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Discover the applications


Investigate the validated core application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix Core

cnb1476_physiomimix-core_mark_mocks_system_v2
Learn more

Consumables

Multi-chip plates
3D validated cells
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

May 21, 2026

Event > Conference >

The Sensor Decade 2026 Conference


The biennial meeting brings together leading researchers, innovative companies, and regulators to share knowledge and expertise, to accelerate the development of new ideas.

TSD 2026 Logo | The Sensor Decade 2026
3 - 4 June, 2026
Oslo, Norway
Book a meeting

We’re excited to present at The Sensor Decade 2026 Conference (TSD 2026).

Sensors are central to Europe’s transformation agendas. They create a vital link between the physical and digital worlds. The Sensor Decade’s grand challenges include – Sensing the Planet to safeguard climate, oceans and food systems. Sensing the Body for health, medtech and microsurgery. Sensing the Engineered World for autonomy, robotics and industry. and Sensing the Invisible to unlock quantum, photonics and nanotechnology. The conference explores the full spectrum of enabling technologies from sensor materials, integration, chip design and microfabrication, multimodal and AI-enhanced sensing, advances in physics, and solutions that support sustainability and circularity.

This year, the focus of the conference is the expansion of the sensor value chain at both ends: with quantum sensors opening new physical frontiers, and AI-enhanced sensing unlocking greater value from data.


Attend our​ presentation:

How sensors are key for the next generation of Organ-on-a-chip devices

Organ-on-a-chip (OOC) technologies, also known as microphysiological systems (MPS), are an advancing, and increasing key, technology in the field of cell culturing. Such systems facilitate the growth of complex, three-dimensional cell cultures with structures and functionalities far closer to those seen in vivo than are present in traditional two-dimensional cell culturing. By the introduction of scaffolding and controlled fluidic flow a greater, and more physiologically relevant, set of phenotypes can be expressed. This allows for more complex and sophisticated studies to be carried out, sitting at a critical point between 2D in vitro and animal in vivo in the drug discovery process, capable of producing responses superior to either model. Recent changes in regulatory approach in both the US and UK now make microphysiological systems viable methods for the reduction of pharmaceutical animal testing. The resultant interest and uptake bring greater demands in terms of accessibility, throughput, and data volume, challenging current measurement capabilities. This need represents an excellent opportunity for the introduction and integration of real-time sensing to increase data quality and experimental confidence. From dissolved gases to small molecules to complex proteins, sensing of key indicators promises to be transformative in adoption and impact of this nascent technology.

Date: 03 June 2026, Wednesday

Time: 14:30 – 15:00

Room: Store Auditorium

Presenters: Dr Daniel Carney


Meet the team at The Sensor Decade 2026 Conference:

DanC 1 | The Sensor Decade 2026

Dr. Daniel Carney

Principal Engineer

Dr. Daniel Carney is Principal Engineer at CN Bio, leading a team developing and improving the best-in-class PhysioMimix® MPS to provide robust, physiologically relevant environments for 3D cell culturing. He has over 20 years of experience in commercial research and development working in both small start-ups and larger companies in a range of fields including pharmaceuticals, in vitro diagnostic kits, oilfield materials, next-generation sequencing, and medical devices. Daniel holds an MChem in Chemistry and a PhD in Inorganic Materials Chemistry, both from the University of Manchester.

    Find out more about our PhysioMimx Core

    Find out more about the PhysioMimix Multi-chip (Liver-12, Liver-48, Dual Organ , and Barrier) plates.

    The Sensor Decade 2026 Conference

    Book a meeting

    Speak to our experts

    Request a meeting with one of our OOC experts to see how our products and services can support your studies

    Request a meeting

    Footer

    CN Bio logo

    332 Cambridge Science Park, Milton Road
    Cambridge, CB4 0WN

    UK: +44 (0) 1223 737 941

    US: +1 415 523 4005

    Privacy | Cookies | Regulatory | Accessibility
    Website terms | Terms of sale

    Product Recycling

    ©2025 CN Bio Innovations Ltd
    Registered No. ‍06517359. VAT No. GB978184563

    Latest news

    • CN Bio Participating in a New Critical Path Institute Coalition of New Approach Methodologies Developers (NAMs-DC) to Support Advancement in Drug Development May 20, 2026
    • Do MHRA and FDA guidelines on non-animal methods in drug development align? March 27, 2026
    • CN Bio to participate in 3Rs Collaborative-led project with FDA to build confidence in Liver MPS for DILI – now ISTAND accepted! January 25, 2026
    Cyber Essentials Logo

    Modal Title